NCT03915873

Brief Summary

Applying the ISTH-BAT questionnaire on Egyptian patients with type I VWD aiming to correlate the BS with the laboratory findings

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Dec 2019

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 12, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 16, 2019

Completed
8 months until next milestone

Study Start

First participant enrolled

December 1, 2019

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2020

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2021

Completed
Last Updated

September 10, 2019

Status Verified

September 1, 2019

Enrollment Period

1 year

First QC Date

April 12, 2019

Last Update Submit

September 7, 2019

Conditions

Von Willebrand Disease, Type 1

Keywords

von willebrandegyptianquestionnaire

Outcome Measures

Primary Outcomes (1)

  • the International Society on Thrombosis and Hemostasis-Bleeding Assessment Tool (ISTH-BAT)

    Questionnaire minimum score ranges from 0 to 10 whereas maximum score ranges from 20 to 30

    one year

Study Arms (2)

vWB patients

Diagnostic Test: The von Willebrand Antigen level

control

Interventions

The von Willebrand Antigen levelDIAGNOSTIC_TEST

blood sample

vWB patients

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

type 1 von willebrand egyptian patients

You may qualify if:

  • type 1 vWD patients
  • healthy subjects with no known problem with bleeding or bruising were also recruited

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

von Willebrand Disease, Type 1

Condition Hierarchy (Ancestors)

von Willebrand DiseasesBlood Coagulation Disorders, InheritedBlood Coagulation DisordersHematologic DiseasesHemic and Lymphatic DiseasesCoagulation Protein DisordersHemorrhagic DisordersGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
principal investigator

Study Record Dates

First Submitted

April 12, 2019

First Posted

April 16, 2019

Study Start

December 1, 2019

Primary Completion

December 1, 2020

Study Completion

March 1, 2021

Last Updated

September 10, 2019

Record last verified: 2019-09